Richard John Meadows

CTI Life Sciences Fund LP invests in high quality emerging life sciences companies located in Canada. The fund targets companies operating in the fields of pharmaceuticals and biotechnology companies. It provides financing for seed, early and development stage capital requirements. It also act as lead investor.

The Ontario Bioscience Industry Organization is a membership organization that engages in strategy, programming, policy development, and advocacy. The non-profit company is based in Toronto, Canada. The Canadian company was founded by Simon Goulet. Maura Campbell has been the CEO of the company since 2021.

The Ontario Institute For Regenerative Medicine provides stem cell and regenerative medicine research services. The company was founded by on November 25, 2014 and is headquartered in Toronto, Canada.

Phost’In SAS operates as a biotechnology company, which engages in the discovery and development of N-glycosylation inhibitors. Its potent anti-cancer new chemical entities specifically targeting abnormal pathogenic glycosylation mechanisms. The company was founded by Karine Chorro and Ludovic Clarion in December 2014 and is headquartered in France.

CDP Capital Technology Ventures is a venture capital firm that invests in technology companies. The firm provides funding for companies in various stages of development, from early-stage startups to established businesses. CDP Capital Technology Ventures focuses on companies in the information technology, telecommunications, and life sciences sectors. The firm is a subsidiary of Caisse de dépôt et placement du Québec, one of Canada's largest institutional fund managers, and ultimately controlled by the Province of Québec.

Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada.

NeurAxon, Inc. is engaged in the research and development of growing and unmet needs for chronic pain management. It is focused on developing pain therapeutics targeting neuronal Nitric Oxide Synthase (nNOS) inhibitors. The companyw as founded in 2004 and is headquartered in Mississauga, ON.

CDP Capital Private Equity (CDPQ) is a private equity subsidiary of The Caisse de dépôt et placement du Québec founded in 1995. The firm is headquartered in Montréal with additional office in London.